miRNA Plasmid Composition for Serotonin mRNA Silencing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Dysregulation of bioactive molecules, such as serotonin receptors, leads to homeostatic imbalance and disease, necessitating therapies to regulate their expression.

Innovation Solution

Compositions comprising recombinant plasmids that encode for micro-interfering ribonucleic acid (miRNA) sequences targeting serotonin receptor mRNAs, increasing endogenous production of miRNA to degrade or inactivate these receptors, thereby reducing their bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If serotonin receptor expression is increased to enhance neurotransmission, then neurological function is improved, but homeostatic imbalance and disease occur due to over-expression

Engineering Contradiction:
Improveserotonin receptor expressionVSAvoidhomeostatic balance
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent employs miRNA as a negative feedback mechanism to downregulate serotonin receptor expression when it becomes excessive. The recombinant plasmid delivers miRNA sequences that specifically target and degrade serotonin receptor mRNA, creating a self-regulating system that maintains homeostatic balance by counteracting over-expression.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The invention changes the expression parameter of serotonin receptors from a static state to a dynamically regulated state. By introducing recombinant plasmids that encode miRNA, the system can modulate receptor expression levels in response to physiological conditions, transitioning from fixed expression to adaptable parameter control.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If miRNA production is upregulated to degrade target mRNA, then bioavailability of target biomolecule is decreased, but production efficiency of therapeutic effect is improved

Engineering Contradiction:
ImprovemiRNA productionVSAvoidbioavailability of target biomolecule
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The patent extracts and utilizes the natural RNA interference mechanism by introducing recombinant plasmids that encode miRNA sequences. These plasmids are taken up by cells and processed into functional miRNA molecules that selectively bind to and degrade target mRNA, effectively removing the target biomolecule's instructional information without directly removing the biomolecule itself.

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively downregulate serotonin receptor expression, restoring homeostasis and potentially treating associated diseases by enhancing miRNA production within cells.

Implementation Method 1

the miRNA can cause the target mRNA to be degraded or inactivated

Methodology Applied
Scientific EffectRNA interference:

Implementation Method 2

The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA)

Methodology Applied
Scientific EffectComplementary base pairing:

Implementation Method 3

a backbone sequence of nucleic acids that facilitates introduction of the one or more insert sequences into one or more of a subject's cells

Methodology Applied
Scientific EffectTransfection:

Data Source

PatentUS12540328B2Composition for regulating production of interfering ribonucleic acid
Publication Date: 2026.02.03 WYVERN PHARMACEUTICALS INC

AI summary

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.